Unacknowledged Casualties — The Issue
What Happened,
Who Was Harmed,
and Why It Matters Now
A structured overview of the ADF quinoline drug trials, their documented consequences, and the institutional failures that have left families without recognition or support for more than twenty-five years.
This page is designed as an entry point for journalists, policymakers, legal professionals, and researchers encountering this issue for the first time. All claims are evidentially registered. Primary sources are listed on the About This Site page.
Between 1998 and 2002, the Australian Defence Force administered two antimalarial drugs — mefloquine and tafenoquine — to approximately 3,000 personnel deployed to East Timor and Bougainville. In significant part, these administrations were formal clinical drug trials. Both drugs are now recognised by major regulatory agencies as capable of causing serious and potentially permanent neurological damage.
The harm documented among affected veterans is substantial and has been the subject of Senate inquiries, a Royal Commission, and peer-reviewed scientific literature spanning three decades. But there is a dimension of this harm that has received almost no institutional attention: what happened to the families.
The partners, spouses, and children of affected veterans — people who did not deploy, did not consent, and were not told what the drugs might do — have been living with the domestic consequences of those neurological injuries for more than twenty-five years. No policy framework recognises them. No support program exists for them. No government has apologised to them.
This site documents what happened, why it matters, and what must change.
What Happened
Between 1998 and 2002, the Australian Defence Force deployed approximately 3,000 personnel to East Timor and Bougainville. As part of those deployments, personnel were administered two antimalarial drugs: mefloquine (brand name Lariam) and tafenoquine. In significant part, these administrations were formal clinical drug trials conducted by the Army Malaria Institute.
The scale of the trials was substantial. An estimated 1,319 ADF personnel participated in mefloquine trials in East Timor alone. More than 1,540 were enrolled in tafenoquine studies across both deployment theatres.
The dosing conditions were extreme by clinical standards. The approved prophylactic dose of mefloquine is 250 mg per week. During the AMI trials, personnel received loading doses of 750 mg per week, with some subjects receiving up to 1,500 mg per week — six times the approved level. Tafenoquine trial subjects received up to 1,200 mg over three days.
Personnel were not always adequately informed of what they were being given or why. The consent process did not meet contemporary clinical trial standards. No longitudinal follow-up health studies have ever been conducted on the tafenoquine trial subjects.
Evidential register: Established — drawn from Senate inquiry records, Royal Commission Final Report (2024), and QVFA Submission 94. Specific dosing figures should be verified against primary AMI trial records for formal or legal use.What the Drugs Can Do
Both mefloquine and tafenoquine are recognised by major regulatory agencies as carrying substantial neuropsychiatric risk. The regulatory record is clear and publicly accessible.
| Regulatory Action | Agency | Year | Key Finding |
|---|---|---|---|
| Black box warning — mefloquine | US FDA | 2013 | Neuropsychiatric adverse reactions may persist after the drug is discontinued and may in some cases become permanent. Psychiatric symptoms including paranoia, psychosis, and suicidal ideation may continue for months or years after the drug is stopped. |
| Strengthened warnings — mefloquine | TGA (Australia) | Ongoing | Parallel strengthened warnings consistent with FDA position. Product data sheet lists paranoia, hallucinations, psychosis, dissociation, aggression, and suicidal ideation as uncommon adverse effects. |
| Boxed warnings — psychiatric prodromal signs | EMA (Europe) | 2014–2017 | Required boxed warnings for psychiatric symptoms as prodromal signs of more serious events. Acknowledged potential for permanent brain damage. |
| Tafenoquine neurotoxicity finding | WRAIR (US Army) | 2009 | Tafenoquine found to be more neurotoxic than mefloquine — a drug already classified by the ADF as a drug of last resort. No follow-up health studies were initiated for the 1,540 ADF trial subjects. |
The harms documented among affected veterans include chronic depression, anxiety, paranoia, delusional disorder, psychosis, hallucinations, personality change, aggression, dissociation, vestibular disorders, seizures, and suicide. They also include — though this has received almost no institutional attention — domestic violence, coercive control, and lethal family violence directed at partners and children.
Evidential register: Established (FDA, TGA, EMA documentation; peer-reviewed literature).Domestic violence nexus: Plausible mechanism and documented case evidence — direct causation in individual cases not asserted beyond what the peer-reviewed literature supports.
The Neurological Mechanism
At toxic concentrations, mefloquine and tafenoquine cause injury to three brain regions with direct relevance to behaviour in the domestic environment. This is not a theoretical connection — it is the documented neurological consequence of pharmacological injury to the specific brain systems that regulate intimate relational behaviour.
The Limbic System
Governs emotional regulation, threat detection, impulse control, empathy, and the modulation of fear and rage. Limbic damage is associated with disinhibited aggression, paranoid threat perception, and emotional dysregulation — the neurological substrate of the domestic violence risk documented in this report.
The Brainstem
Regulates the autonomic nervous system and arousal states. Brainstem toxicity produces chronic hyperarousal — a nervous system locked in sustained fight-or-flight — with associated irritability, reactivity, and dramatically reduced inhibitory control over emotional and behavioural responses.
The Vestibular System
Controls balance and spatial orientation. Vestibular disruption produces chronic dizziness, disorientation, and disequilibrium — associated with heightened anxiety and persistent distress that compounds behavioural volatility produced by limbic and brainstem injury.
CYP2D6 and Differential Susceptibility
Not everyone who took these drugs experienced severe effects. A plausible biological mechanism for differential susceptibility has been identified in the CYP2D6 enzyme pathway. Poor or intermediate metabolisers — estimated at 12 to 23 percent of Caucasian populations — may be unable to clear quinoline compounds before toxic concentrations accumulate. Every ADF tafenoquine trial subject who voluntarily underwent CYP2D6 testing returned a poor or intermediate metaboliser result.
The symptoms of quinoline-induced neurotoxicity are clinically indistinguishable from PTSD on standard psychiatric assessment. Both conditions produce hyperarousal, nightmares, rage, paranoid ideation, dissociation, and suicidal ideation. The result, documented as nearly universal in the affected cohort, is misdiagnosis as PTSD — and treatment calibrated to the wrong condition, indefinitely, leaving the neurological substrate of dangerous behaviour unaddressed.
The Spouse and Partner
The woman who did not deploy, did not consent to the drug trial, was not briefed on the neuropsychiatric risks of the compounds administered to her partner, and signed no form. No institution monitored her welfare. No system exists to recognise her injury. She is, in the strictest sense, invisible to every relevant institution — DVA, family court, domestic violence services, and the legal system. She is the primary subject of this site.
The Children
Children in these households were exposed to a parent's quinoline-induced neurological injury during the years in which their own brains and nervous systems were forming. They were not told what was causing what they witnessed. They have no DVA pathway, no clinical category, and no welfare program. The developmental consequences of their exposure are real, consistent with the ACE research literature, and entirely unacknowledged by any institution.
The Veteran
The veteran is not the primary subject of this site — but the veteran's harm is the origin of the harm to the family. This site does not attribute moral blame to veterans whose behaviour may reflect pharmacological brain injury. The harm documented here is systemic. The veteran is also a casualty of the institutional decisions that produced it. Recognising the family does not diminish the veteran's claim — it extends it.
The Royal Commission asked the right questions about veterans. The questions about their families have not yet been asked — let alone answered. This site documents what those questions are, what the evidence says, and what must change.Unacknowledged Casualties Research Report, 2026
Why It Matters Now
The institutional landscape changed significantly in 2024 — but the change did not extend to families. The following timeline identifies what has shifted and what has not.
Royal Commission Final Report Tabled
The Royal Commission into Defence and Veteran Suicide tabled its Final Report. Volume 4, Chapter 22 addressed mefloquine and tafenoquine directly and recommended a brain injury program for serving and ex-serving members exposed to these drugs — representing the first official acknowledgement that quinoline toxicity is a legitimate medical issue requiring a dedicated response.
Government Accepts Recommendations in Principle
The Australian Government accepted or agreed in principle to 104 of the Commission's 122 recommendations. Work on the brain injury program is reported to be underway. The long-standing official denial that quinoline toxicity is a legitimate medical issue is no longer the government's stated position.
Spouses and Children: Not Included
The brain injury program does not extend to spouses, partners, or children. The Statement of Principles gap for acquired brain injury in the DVA entitlements system has not been resolved. Domestic violence services have received no guidance specific to quinoline-related neurotoxicity. Family courts operate without any framework for the neurological context. Coroners are not required to obtain AMI pharmaceutical records. No compensation mechanism exists for secondary casualties.
The Questions About Families Have Not Been Asked
The Royal Commission's recommendations represent progress for veterans. They represent nothing for the partners and children who bore the domestic consequences of the same institutional decisions. The window created by the Royal Commission — in which the government has acknowledged the problem and committed to action — is the right moment to demand that the acknowledgement extend to families. That is what this site exists to do.
What Remains Unchanged
The following gaps have not been addressed by the Royal Commission's recommendations, the government's December 2024 response, or any other institutional action. They are identified here as the specific targets of the reforms this site calls for.
- No DVA mechanism exists by which a spouse or partner can make a claim for harm sustained as a consequence of a veteran's quinoline drug trial injury. There is no category of secondary casualty. There is no SOP for acquired domestic harm.
- No domestic violence service in Australia has a protocol for identifying, assessing, or supporting women affected by quinoline-related harm. The features that distinguish this population — the neurological origin of the behaviour, the episodic nature of the risk, the veteran context — are not part of any current training or assessment framework.
- No family court in Australia has access to judicial or expert guidance that incorporates quinoline toxicity as a recognised neurological context relevant to assessing domestic violence risk, parenting capacity, or child safety. Family courts continue to make decisions about these families without the information they need.
- Coroners investigating deaths in ADF veteran families — suicides, homicides, family violence fatalities — are not required to obtain the veteran's pharmaceutical record from AMI and ADF sources. The quinoline nexus has therefore never been formally examined in the Australian coronial record.
- No longitudinal research has been commissioned on domestic violence and family harm outcomes in the quinoline veteran cohort. The absence of research is not evidence that the harm is small. It is evidence that no institution has been required to look.
- No country — not Australia, the United States, the United Kingdom, or Canada — has established a recognition or support framework for the secondary harm to families of quinoline-affected veterans. The universal gap reflects a structural assumption embedded in every veterans' welfare system: that the family is a support resource for the veteran, not a population that may itself have been harmed by military decisions.
What This Site Contains
This site is organised as a research report made accessible to multiple audiences. The pages below address different dimensions of the issue, from scientific background to personal testimony to institutional analysis. They can be read in sequence or navigated directly to the most relevant section.
Beginner's Introduction
Plain-language overview for readers with no prior knowledge of the issue — what happened, what the drugs did, and what the consequences were for families.
The Quinoline Era
The history of the trials — the timeline, the drugs, the dosing conditions, and the regulatory record from the 1960s to 2024.
Coercive Control in the Home
How quinoline neurotoxicity produced the specific behavioural patterns documented in affected households — each linked to its neurological mechanism.
Just the Army Wife
The structural position of the military spouse — and what "just the army wife" meant for recognition, entitlement, and recourse when things went wrong.
Left Behind — Spouses and Children
What makes these families different from other military families, why the government has turned away, and what the delay is costing in human terms.
It Was Not You — For the Veteran
Written directly for affected veterans: the neurological mechanism, the misdiagnosis, and what understanding the pharmacological origin changes.
It Was Not His Personality
Why the changes families witnessed were neurological, not character-driven — and why the word narcissism, however understandable, was the wrong explanation.
The Children
Children as a distinct harm population — what they were exposed to, what the ACE research shows, and why they were never given an explanation.
She Was Left With Nothing
The most direct page on this site — for women who lost the most. The chain of failures that brought them there. The grief, the financial devastation, the loss of children. Written without softening.
What You Can Do
Specific actions for journalists, policymakers, lawyers, clinicians, researchers, and members of the public — organised by what each group can do with the leverage they have.
For Families
Direct address for partners, former partners, and children — with crisis resources, page directory, and the most important thing this site says to them.
About This Site
Transparency page — evidential registers, source disclosure, causation framing, key sources, and download link for the full research report.
The spouses and children of ADF quinoline veterans were not soldiers. They did not choose to participate in a drug trial. They were not briefed on the risks. No institution monitored their welfare. No system exists to recognise their injury.
They are the casualties of a trial they never knew was happening. They have waited long enough.
Unacknowledged Casualties — Research Report 2026